CHI3L1表达水平与4种心血管疾病的因果关系:一项双样本的孟德尔随机化研究

doi:10.3969/j.issn.1674-490X.2026.01.002

摘要/Abstract

摘要： 目的探讨几丁质酶-3样蛋白1(Chitinase-3-like protein 1,CHI3L1)与4种心血管疾病(高血压心脏病、心力衰竭、冠状动脉疾病、心肌梗死)之间是否存在因果关系。方法采用双样本孟德尔随机化方法,使用逆方差加权法、加权中位数和孟德尔随机化艾格回归法进行效应评估。结果 3种分析方法都没有显示CHI3L1与4种心血管疾病存在遗传因果证据(P>0.05)。结论本研究未能从遗传学角度证实CHI3L1是心血管疾病的致病原因。

关键词: 孟德尔随机化, 几丁质酶-3样蛋白1, 心血管疾病, 心力衰竭, 心肌梗死

Abstract: Objective To investigate whether there is a causal relationship between Chitinase-3-like protein 1(CHI3L1)and four cardiovascular diseases(hypertensive heart disease, heart failure, coronary artery disease, myocardial infarction). Methods This study employed a two-sample Mendelian randomization approach, using inverse-variance weighted, weighted median, and MR-Egger methods for effect estimation. Results All analytical methods showed that there was no significant genetic evidences supporting a causal role of CHI3L1 in the four cardiovascular diseases(P>0.05). Conclusion This study does not provide that genetic evidences could result in a causal role of CHI3L1 in the development of cardiovascular diseases.

Key words: Mendelian randomization, Chitinase-3-like protein 1, cardiovascular disease, heart failure, myocardial infarction

中图分类号:

R541
R543

王奕娇,李晓珊,段泽森,曹梦云,张俊玲. CHI3L1表达水平与4种心血管疾病的因果关系:一项双样本的孟德尔随机化研究[J]. 医学研究与教育, 2026, 43(1): 11-19.

WANG Yijiao, LI Xiaoshan, DUAN Zesen, CAO Mengyun, ZHANG Junling. Association between CHI3L1 expression levels and four cardiovascular diseases: a two-sample Mendelian randomization study[J]. Journal of Hebei Medical College for Continuing Education, 2026, 43(1): 11-19.

参考文献

[1] BLAZEVIC N, ROGIC D, PELAJIC S, et al. YKL-40 as a biomarker in various inflammatory diseases: a review[J]. Biochem Med, 2024, 34(1): 010502. DOI: 10.11613/BM.2024.010502.
[2] OYELEYE A, NORMI Y M. Chitinase: diversity, limitations, and trends in engineering for suitable applications[J]. Biosci Rep, 2018, 38(4): BSR2018032300. DOI: 10.1042/bsr20180323.
[3] LI H, GREENE L H. Sequence and structural analysis of the chitinase insertion domain reveals two conserved motifs involved in chitin-binding[J]. PLoS One, 2010, 5(1): e8654. DOI: 10.1371/journal.pone.0008654.
[4] FUSETTI F, PIJNING T, KALK K H, et al. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39[J]. J Biol Chem, 2003, 278(39): 37753-37760. DOI: 10.1074/jbc.M303137200.
[5] XU Q Y, SUN L L, WANG Y N, et al. Causal effects of YKL-40 on ischemic stroke and its subtypes: a 2-sample Mendelian randomization study[J]. J Am Heart Assoc, 2023, 12(17): e029000. DOI: 10.1161/jaha.122.029000.
[6] VOLCK B, PRICE P A, JOHANSEN J S, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils[J]. Proc Assoc Am Physicians, 1998, 110(4): 351-360.
[7] HOUSTON D R, RECKLIES A D, KRUPA J C, et al. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes[J]. J Biol Chem, 2003, 278(32): 30206-30212. DOI: 10.1074/jbc.M303371200.
[8] LEE C M, HE C H, NOUR A M, et al. IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses[J]. Nat Commun, 2016, 7: 12752. DOI: 10.1038/ncomms12752.
[9] ZHOU Y, HE C H, YANG D S, et al. Galectin-3 interacts with the CHI3L1 axis and contributes to hermansky-pudlak syndrome lung disease[J]. J Immunol, 2018, 200(6): 2140-2153. DOI: 10.4049/jimmunol.1701442.
[10] ARNETT D K, BLUMENTHAL R S, ALBERT M A, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Circulation, 2019, 140(11): e563-e595. DOI: 10.1161/CIR.0000000000000677 DOI:10.1161/CIR.0000000000000677.
[11] DENG Y J, LI G Y, CHANG D, et al. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases[J]. Clin Chim Acta, 2020, 511: 40-46. DOI: 10.1016/j.cca.2020.09.035.
[12] WEI H, LIU Y D, WANG C, et al. YKL-40 aggravates early-stage atherosclerosis by inhibiting macrophage apoptosis in an aven-dependent way[J]. Front Cell Dev Biol, 2021, 9: 752773. DOI: 10.3389/fcell.2021.752773.
[13] TAN Y F, JI X Y, MO Z F, et al. Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment[J]. Medicine, 2019, 98(47): e17950. DOI: 10.1097/MD.0000000000017950.
[14] YU J E, YEO I J, HAN S B, et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer[J]. Exp Mol Med, 2024, 56(1): 1-18. DOI: 10.1038/s12276-023-01131-9.
[15] SONG M W, ZHANG G F, SHI H, et al. Serum YKL-40 in coronary heart disease: linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events[J]. Front Cardiovasc Med, 2023, 10: 1242339. DOI: 10.3389/fcvm.2023.1242339.
[16] KUCUR M, ISMAN F K, KARADAG B, et al. Serum YKL-40 levels in patients with coronary artery disease[J]. Coron Artery Dis, 2007, 18(5): 391-396. DOI: 10.1097/MCA.0b013e328241d991.
[17] HARUTYUNYAN M, GØTZE J P, WINKEL P, et al. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial[J]. Immunobiology, 2013, 218(7): 945-951. DOI: 10.1016/j.imbio.2012.10.015.
[18] XU T, ZHENG X W, WANG A L, et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: a population-based nested case-control study in China[J]. J Cell Mol Med, 2021, 25(2): 919-924. DOI: 10.1111/jcmm.16148.
[19] RIDKER P M, CHASMAN D I, ROSE L, et al. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene(CHI3L1), and incident cardiovascular events[J]. J Am Heart Assoc, 2014, 3(3): e000897. DOI: 10.1161/JAHA.114.000897.
[20] FOLKERSEN L, FAUMAN E, SABATER-LLEAL M, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease[J]. PLoS Genet, 2017, 13(4): e1006706. DOI: 10.1371/journal.pgen.1006706.
[21] BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525. DOI: 10.1093/ije/dyv080.
[22] BURGESS S, SCOTT R A, TIMPSON N J, et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors[J]. Eur J Epidemiol, 2015, 30(7): 543-552. DOI: 10.1007/s10654-015-0011-z.
[23] VERBANCK M, CHEN C Y, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50(5): 693-698. DOI: 10.1038/s41588-018-0099-7.
[24] BURGESS S, THOMPSON S G. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377-389. DOI: 10.1007/s10654-017-0255-x.
[25] KJAERGAARD A D, JOHANSEN J S, BOJESEN S E, et al. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases[J]. Crit Rev Clin Lab Sci, 2016, 53(6): 396-408. DOI: 10.1080/10408363.2016.1190683.
[26] FANG C Y, CHEN Z F, ZHANG J, et al. The value of serum YKL-40 and TNF-α in the diagnosis of acute ST-segment elevation myocardial infarction[J]. Cardiol Res Pract, 2022, 2022: 4905954. DOI: 10.1155/2022/4905954.
[27] TANG H, SUN Y, SHI Z Q, et al. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK(JNK and ERK)and NF-κB pathways, causing bronchial smooth muscle proliferation and migration[J]. J Immunol, 2013, 190(1): 438-446. DOI: 10.4049/jimmunol.1201827.
[28] JANKOWSKA-KONSUR A, ŁYKO M, RUBAS K, et al. Chitinase-3-like protein 1(YKL-40): a new biomarker of inflammation in pyoderma gangrenosum[J]. Acta Derm Venereol, 2022, 102: 978. DOI: 10.2340/actadv.v101.978.
[29] LIBREROS S, GARCIA-AREAS R, SHIBATA Y, et al. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model[J]. Int J Cancer, 2012, 131(2): 377-386. DOI: 10.1002/ijc.26379.
[30] JUNG Y Y, KIM K C, PARK M H, et al. Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice[J]. Theranostics, 2018, 8(3): 749-766. DOI: 10.7150/thno.20183.
[31] MAROTT S C W, BENN M, JOHANSEN J S, et al. YKL-40 levels and atrial fibrillation in the general population[J]. Int J Cardiol, 2013, 167(4): 1354-1359. DOI: 10.1016/j.ijcard.2012.04.006.
[32] XU T, ZHONG C K, WANG A L, et al. YKL-40 level and hypertension incidence: a population-based nested case-control study in China[J]. J Am Heart Assoc, 2016, 5(11): e004534. DOI: 10.1161/JAHA.116.004534.
[33] WURM J, BEHRINGER S P, RAVI V M, et al. Astrogliosis releases pro-oncogenic chitinase 3-like 1 causing MAPK signaling in glioblastoma[J]. Cancers, 2019, 11(10): 1437. DOI: 10.3390/cancers11101437.
[34] CONNOLLY K, LEHOUX M, O'ROURKE R, et al. Potential role of chitinase-3-like protein 1(CHI3L1/YKL-40)in neurodegeneration and Alzheimer's disease[J]. Alzheimers Dement, 2023, 19(1): 9-24. DOI: 10.1002/alz.12612.
[35] BALDACCI F, LISTA S, PALERMO G, et al. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development[J]. Expert Rev Proteom, 2019, 16(7): 593-600. DOI: 10.1080/14789450.2019.1628643.
[36] DE ROBERTIS M, GRECO M R, CARDONE R A, et al. Upregulation of YKL-40 promotes metastatic phenotype and correlates with poor prognosis and therapy response in patients with colorectal cancer[J]. Cells, 2022, 11(22): 3568. DOI: 10.3390/cells11223568.
[37] LUO Q, FAN J T, LI L L. Silencing YKL-40 gene can inhibit inflammatory factor expression and affects the effect of THP-1 cells on endometrial cancer[J]. Arch Gynecol Obstet, 2022, 305(2): 467-473. DOI: 10.1007/s00404-021-06194-5.
[38] HAO H L, CHEN H Q, XIE L W, et al. YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition[J]. Ann Med, 2021, 53(1): 1170-1178. DOI: 10.1080/07853890.2021.1950920.
[39] YU H H, WANG Z Y, ZHU B W, et al. A humanized Anti-YKL-40 antibody inhibits tumor development[J]. Biochem Pharmacol, 2024, 225: 116335. DOI: 10.1016/j.bcp.2024.116335.
[40] LEONARDI S, PARISI G F, CAPIZZI A, et al. YKL-40 as marker of severe lung disease in cystic fibrosis patients[J]. J Cyst Fibros, 2016, 15(5): 583-586. DOI: 10.1016/j.jcf.2015.12.020.